NAICS 325414: Biological Product
This U.S. industry comprises establishments primarily engaged in manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic).

ExioML sector: Chemicals nec
Region: US | Year: 2022
Sector value added: 183879.917188 M EUR | Employment: 2033.54236812 thousand persons
Sector GHG emissions: 125728834468.0 kg CO2 eq | Energy carrier net total: 3186425.50957 TJ | Carbon intensity: 0.6837551179635024

Company: Exelixis Inc
At Exelixis, cancer is our cause. Over the course of the past three decades, we've evolved into a multi-platform cancer company dedicated to creating treatment regimens that challenge the status quo and bring us closer to a potential cure – all to give more patients hope for the future.